Memorial Sloan Kettering Cancer Center is pleased to announce:

# Advances in Colorectal Oncology: The Multidisciplinary Approach



Friday-Saturday, November 11-12, 2016

Conference Location:

Memorial Sloan Kettering Cancer Center Zuckerman Research Center 417 East 68th Street New York, NY 10065



www.mskcc.org/colorectalcourse


# Course Faculty

#### **MSK Course Directors**



# Garcia-Aguilar, MD, PhD Chief Attending, Colorectal Service,

Chief Attending, Colorectal Service, Benno C. Schmidt Chair in Surgical Oncology, Department of Surgery



### Leonard Saltz, MD

Chief Attending, Gastrointestinal Oncology Service, Department of Medicine



#### Garrett Nash, MD, MPH, FACS, FASCRS

Associate Attending, Colorectal Service, Department of Surgery

## **MSK Faculty**

#### Andrea Cercek, MD

Assistant Attending Physician, Department of Medicine

#### Zana Correa, NP

Nurse Practitioner, Department of Surgery

#### Christopher Crane, MD

Attending Radiation Oncologist, Department of Radiation Oncology

#### Seth Felder, MD

Fellow

Fellow, Department of Surgery

#### Karuna Ganesh, MD

Department of Medicine

#### Marc Gollub, MD, FACR

Attending Radiologist, Department of Radiology

#### Jose Guillem, MD, MPH, FACS, FASCRS

Attending Surgeon, Department of Sugery

#### William Jarnagin, MD, FACS

Chief Attending, Hepatopancreatobiliary Service, Benno C. Schmidt Chair in Surgical Oncology

#### Lee Jones, PhD

Attending Physiologist, Department of Neurology

#### Nancy Kemeny, MD

Attending Physician, Department of Medicine

#### David Kleiman, MD

Colorectal Surgery Fellow, Memorial Sloan Kettering Cancer Center New York Presbyterian Hospital

#### T. Peter Kingham, MD, FACS

Associate Attending Surgeon, Department of Surgery

#### Geoffrey Yuyat Ku, MD

Assistant Attending Physician, Department of Medicine

#### Arnold Markowitz, MD

Attending Physician, Department of Medicine

#### Philip Paty, MD

Attending Surgeon, Department of Surgery

#### Deepthi Rao, MD

Fellow, Department of Pathology

#### Mark Schattner, MD, FACP, CNSP

Attending Physician, Department of Medicine

#### Armin Shahrokni, MD, MPH

Assistant Attending Physician, Department of Medicine

#### Jinru Shia, MD

Attending Pathologist, Department of Pathology

#### J. Joshua Smith, MD, PhD

Assistant Attending Surgeon, Department of Surgery

#### Constantinos Sofocleous, MD, PhD

Attending Radiologist, Department of Radiology

#### David Solit, MD

Attending Physician, Office of Physician-In-Chief

#### Zsofia Stadler, MD

Assistant Attending Physician, Department of Medicine

#### Martin Weiser, MD

Attending Surgeon, Department of Surgery

#### Elizabeth Siryeon Won, MD

Assistant Attending Physician, Department of Medicine

#### Abraham Jing-Ching Wu, MD

Assistant Attending
Radiation Oncologist,
Department of Radiation Oncology

#### Rona Denit Yaeger, MD

Assistant Attending Physician, Department of Medicine

# **Guest Faculty**

#### Larissa Temple, MD, MSc, FACS

Chief of the Division of Colorectal Surgery, University of Rochester Medical Center Rochester, NY



# **Course Overview**

The overall objective of this course is to update the learner on the recent progress made in the treatment of colorectal cancer. This will be achieved by lectures and interactive audience participation encouraging the intellectual exchange of ideas between faculty and participants.

#### **EDUCATIONAL OBJECTIVES**

- Appreciate the importance of a multidisciplinary approach to diagnosis and treating colorectal cancer
- Learn the new advances in genomic typing and its implications for novel therapies in colorectal cancer
- Understand the contemporary endoscopic and minimally invasive surgical approaches to colorectal cancer
- Learn the importance of outcomes measurement, surveillance and survivorship program in colorectal cancer patients
- Understand the treatment options for patients with metastatic colorectal cancer

#### TARGET AUDIENCE

The target audience includes medical oncologists, radiation oncologists, surgical oncologists, colorectal surgeons, gastroenterologists and specialists in internal medicine.

www.mskcc.org/colorectalcourse

# Friday, November 11, 2016

12:30-1:30 LUNCH

7:00-8:00	REGISTRATION & BREAKFAST	SESSIC	SSION III	
8:00-8:10	<b>Opening Remarks</b> Julio Garcia-Aguilar, MD, PhD	MODERATOR	Garrett Nash, MD, MPH, FACS, FASCRS	
SESSION I		1:30-1:45	Chemotherapy	
MODERATOR 8:10-9:00	Julio Garcia-Aguilar, MD, PhD  DEPARTMENT OF MEDICINE		Controversies: Should Stage II Patient Get Chemotherapy? Elizabeth Siryeon Won, MD	
8.10-9.00	GRAND ROUNDS	1:45-2:00	Setting Up A Survivorship	
	Recent MSKCC Advances in Understanding the Molecular	1.43-2.00	Program	
	Biology of Colorectal Cancer		Zana Correa, NP	
9:00-9:15	David Solit, MD  Genotyping Colorectal Cancer: Implications in Clinical Management Rona Denit Yaeger, MD	2:00-2:15	Incorporating Patient Reported Outcomes into Colorectal Cancer Care Larissa Temple, MD, MSc, FACS	
9:15-9:30	Recognizing Hereditary Colorectal Cancer: When Referral and Testing Should Be Undertake Zsofia Kinga Stadler, MD	2:15-2:30	A Translational Approach to the Development and Testing of Exercise Treatment in Colorectal Cancer Lee Jones, PhD	
9:30-9:45	Choosing the Right Operation for the Patient with Hereditary Colorectal Cancer Jose Guillem,	2:30-2:45	Chemotherapy Controversies: Looking Beyond Age for Treatment Decision Making Armin Shahrokni, MD, MPH	
	MD, MPH, FACS, FASCRS	2:45-3:15	Session III Panel Discussion	
9:45-10:00	Prognosis of Colon Cancer Beyond TNM	3:15-3:30	BREAK	
	•		ON IV	
	Jinru Shia, MD	SESSIC	ON IV	
10:00-10:30	Jinru Shia, MD Session 1 Panel Discussion	SESSIC MODERATOR	ON IV  Christopher Crane, MD	
10:00-10:30 10:30-10:45	Session 1 Panel Discussion		Christopher Crane, MD Unresectable Metastatic	
	Session 1 Panel Discussion  BREAK	MODERATOR	Christopher Crane, MD	
10:30-10:45	Session 1 Panel Discussion  BREAK	MODERATOR	Christopher Crane, MD Unresectable Metastatic Disease: Should the Primary Be Removed? J. Joshua Smith, MD, PhD	
10:30-10:45 SESSIC	Session 1 Panel Discussion  BREAK  ON II  Leonard Saltz, MD  Where is it? How Imaging Guides Colon Cancer Resection	MODERATOR	Christopher Crane, MD Unresectable Metastatic Disease: Should the Primary Be Removed?	
10:30-10:45 SESSIC	Session 1 Panel Discussion  BREAK  ON II  Leonard Saltz, MD  Where is it? How Imaging Guides Colon Cancer	MODERATOR 3:30-3:45	Christopher Crane, MD Unresectable Metastatic Disease: Should the Primary Be Removed? J. Joshua Smith, MD, PhD Systemic Chemotherapy: Have we Made Progress Since FolFox?	
10:30-10:45 SESSIC MODERATOR 10:45-11:00	Session 1 Panel Discussion BREAK  ON II  Leonard Saltz, MD  Where is it? How Imaging Guides Colon Cancer Resection Marc Gollub, MD, FACR  Advances in Colon Cancer: Complete Mesocolon Excision Martin Weiser, MD  Can We Treat Colon Cancer with Endoscopic Resection? Mark Schattner,	MODERATOR 3:30-3:45 3:45-4:00	Christopher Crane, MD Unresectable Metastatic Disease: Should the Primary Be Removed? J. Joshua Smith, MD, PhD Systemic Chemotherapy: Have we Made Progress Since FolFox? Leonard Saltz, MD Optimizing Treatment for Locoregional Recurrence of Colon Cancer	
10:30-10:45  SESSIC  MODERATOR 10:45-11:00  11:00-11:15	Session 1 Panel Discussion  BREAK  ON II  Leonard Saltz, MD  Where is it? How Imaging Guides Colon Cancer Resection Marc Gollub, MD, FACR  Advances in Colon Cancer: Complete Mesocolon Excision Martin Weiser, MD  Can We Treat Colon Cancer with Endoscopic Resection? Mark Schattner, MD, FACP, CNSP  Surveillance Type and	MODERATOR 3:30-3:45 3:45-4:00 4:00-4:15	Christopher Crane, MD Unresectable Metastatic Disease: Should the Primary Be Removed? J. Joshua Smith, MD, PhD Systemic Chemotherapy: Have we Made Progress Since FolFox? Leonard Saltz, MD Optimizing Treatment for Locoregional Recurrence of Colon Cancer Phillip Paty, MD What is on the Horizon for Immunotherapy? Clouds or Clear Sky? Leonard Saltz, MD What's New in Management of Liver Metastasis?	
10:30-10:45  SESSIC  MODERATOR 10:45-11:00  11:00-11:15	Session 1 Panel Discussion  BREAK  ON II  Leonard Saltz, MD  Where is it? How Imaging Guides Colon Cancer Resection Marc Gollub, MD, FACR  Advances in Colon Cancer: Complete Mesocolon Excision Martin Weiser, MD  Can We Treat Colon Cancer with Endoscopic Resection? Mark Schattner, MD, FACP, CNSP	MODERATOR 3:30-3:45 3:45-4:00 4:00-4:15 4:15-4:30	Christopher Crane, MD Unresectable Metastatic Disease: Should the Primary Be Removed? J. Joshua Smith, MD, PhD Systemic Chemotherapy: Have we Made Progress Since FolFox? Leonard Saltz, MD Optimizing Treatment for Locoregional Recurrence of Colon Cancer Philip Paty, MD What is on the Horizon for Immunotherapy? Clouds or Clear Sky? Leonard Saltz, MD What's New in Management	
10:30-10:45  SESSIC  MODERATOR 10:45-11:00  11:00-11:15	Session 1 Panel Discussion BREAK  ON II  Leonard Saltz, MD  Where is it? How Imaging Guides Colon Cancer Resection Marc Gollub, MD, FACR  Advances in Colon Cancer: Complete Mesocolon Excision Martin Weiser, MD  Can We Treat Colon Cancer with Endoscopic Resection? Mark Schattner, MD, FACP, CNSP  Surveillance Type and Chemotherapy Prevention Arnold Markowitz, MD  Quality Improvement in	MODERATOR 3:30-3:45 3:45-4:00 4:00-4:15 4:15-4:30 4:30-4:45 4:45-5:15	Christopher Crane, MD Unresectable Metastatic Disease: Should the Primary Be Removed? J. Joshua Smith, MD, PhD Systemic Chemotherapy: Have we Made Progress Since FolFox? Leonard Saltz, MD Optimizing Treatment for Locoregional Recurrence of Colon Cancer Philip Paty, MD What is on the Horizon for Immunotherapy? Clouds or Clear Sky? Leonard Saltz, MD What's New in Management of Liver Metastasis? T. Peter Kingham, MD, FACS Session IV Panel Discussion	
10:30-10:45  SESSIC  MODERATOR 10:45-11:00  11:00-11:15  11:15-11:30	Session 1 Panel Discussion BREAK  ON II  Leonard Saltz, MD  Where is it? How Imaging Guides Colon Cancer Resection Marc Gollub, MD, FACR  Advances in Colon Cancer: Complete Mesocolon Excision Martin Weiser, MD  Can We Treat Colon Cancer with Endoscopic Resection? Mark Schattner, MD, FACP, CNSP  Surveillance Type and Chemotherapy Prevention Arnold Markowitz, MD  Quality Improvement in Colon Cancer Surgery:	MODERATOR 3:30-3:45 3:45-4:00 4:00-4:15 4:15-4:30 4:30-4:45 POSTE	Christopher Crane, MD Unresectable Metastatic Disease: Should the Primary Be Removed? J. Joshua Smith, MD, PhD Systemic Chemotherapy: Have we Made Progress Since FolFox? Leonard Saltz, MD Optimizing Treatment for Locoregional Recurrence of Colon Cancer Phillip Paty, MD What is on the Horizon for Immunotherapy? Clouds or Clear Sky? Leonard Saltz, MD What's New in Management of Liver Metastasis? T. Peter Kingham, MD, FACS Session IV Panel Discussion	
10:30-10:45  SESSIC  MODERATOR 10:45-11:00  11:00-11:15  11:15-11:30	Session 1 Panel Discussion BREAK  ON II  Leonard Saltz, MD  Where is it? How Imaging Guides Colon Cancer Resection Marc Gollub, MD, FACR  Advances in Colon Cancer: Complete Mesocolon Excision Martin Weiser, MD  Can We Treat Colon Cancer with Endoscopic Resection? Mark Schattner, MD, FACP, CNSP  Surveillance Type and Chemotherapy Prevention Arnold Markowitz, MD  Quality Improvement in	MODERATOR 3:30-3:45 3:45-4:00 4:00-4:15 4:15-4:30 4:30-4:45 4:45-5:15	Christopher Crane, MD Unresectable Metastatic Disease: Should the Primary Be Removed? J. Joshua Smith, MD, PhD Systemic Chemotherapy: Have we Made Progress Since FolFox? Leonard Saltz, MD Optimizing Treatment for Locoregional Recurrence of Colon Cancer Philip Paty, MD What is on the Horizon for Immunotherapy? Clouds or Clear Sky? Leonard Saltz, MD What's New in Management of Liver Metastasis? T. Peter Kingham, MD, FACS Session IV Panel Discussion	

# Saturday, November 12, 2016

8:00-8:30 BREAKFAST

#### **SESSION V**

MODERATOR William Jarnagin, MD, FACS

8:30-9:00 Hepatic Arterial Infusion (HAI): Improving Results after Liver Resection and

Making the Unresectable,

Resectable

Nancy Kemeny, MD

9:00-9:20 Cytoreductive Surgery

for Carcinomatosis: Good Patient Selection or Treatment Effect?

Garrett Nash,

MD, MPH, FACS, FASCRS

9:20-9:40 IP Chemotherapy for

Peritoneal Metastasis: Some

Like It Hot!

Andrea Cercek, MD

9:40-10:00 SBRT for Metastatic

Colon Cancer

Abraham Jing-Ching Wu, MD

10:00-10:20 Percutaneous Ablation for

Colorectal Liver Metastasis Constantinos Sofocleous,

MD, PhD

10:20-10:45 Session V Panel Discussion

10:45-11:00 BREAK

#### **CASE PRESENTATIONS**

MODERATOR J. Joshua Smith, MD, PhD

11:00-12:30 Case Presentations

MSKCC Tumor Board

12:30 Adjourn

# **CALL FOR ABSTRACTS**

Participants are invited to submit an abstract for presentation at the meeting. Abstracts for the poster session will be selected on the basis of their scientific merit and content quality. Visit the conference website for more information.

www.mskcc.org/colorectalcourse

# Registration

Physicians (MDs, PhDs, DOs)	\$250
MSK Alliance and MSK Alumni	\$175
Residents, Fellows, NPs, PAs, RNs	\$100
Industry Members*	\$450

#### REGISTER ONLINE:

# www.mskcc.org/colorectalcourse

Registration includes continental breakfast, lunch, and refreshment breaks. Please contact us at least one week prior to the course if you have any special dietary needs.

Registration is complimentary for MSK staff who wish to attend this course. However, you must register online by visiting the Continuing Medical Education page on OneMSK.

#### ACCREDITATION STATEMENT

MSK is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

#### AMA CREDIT DESIGNATION STATEMENT

MSK designates this live activity for a maximum of 12.5 AMA PRA Category 1 Credits<sup>TM</sup>. Physicians should only claim credit commensurate with the extent of their participation in the activity. The AMA has determined that physicians not licensed in the United States but who participate in this CME activity are eligible for 12.5 AMA PRA Category 1 Credits<sup>TM</sup>.

#### **ACCOMMODATIONS**

For information on hotels in the area of MSK with discounted rates, please visit: www.mskcc.org/accommodations.

#### **FACULTY DISCLOSURE**

It is the policy of MSK to make every effort to insure balance, independence, objectivity, and scientific rigor in all continuing medical education activities which it sponsors as an ACCME accredited provider. In accordance with ACCME guidelines and standards, all faculty participating in an activity sponsored by MSK are expected to disclose any significant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services which are discussed by the faculty members in an educational presentation. As required by the ACCME, when an unlabeled use of a commercial product or an investigational use not yet approved for any purpose is discussed during an educational activity, MSK requires the speaker to disclose that the product is not labeled for the use under discussion or that the product is still investigational.

#### CONTACT

Continuing Medical Education Memorial Sloan Kettering Cancer Center 633 Third Avenue, 12th Floor New York, NY 10017 cme@mskcc.org

#### STAY CONNECTED

Stay connected with the course on social media: #MSKColOncCME





Join the MSK CME LinkedIn Group